ArticleInternational journal of general medicine2025
Epidemiologic and Clinical Characteristics of Cancer Patients Presented to the Emergency Service with COVID-19 Symptoms.
Article in International journal of general medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The study aimed to define the clinical characteristics of coronavirus disease (COVID-19) in cancer patients admitted to the emergency service (ES) and to determine the parameters associated with mortality. Patients and methods: The data of patients with COVID-19 symptoms and solid or hematological malignancies under anticancer treatment, who presented to the ES between March 1, 2020, and March 31, 2021, and underwent RT-PCR (Real-Time Polymerase Chain Reaction) testing, were evaluated. Demographic, clinical, and laboratory parameters were compared between COVID-19-negative and COVID-19-positive groups, as well as between survivor and non-survivor groups in COVID-19-positive patients. Parameters associated with poor prognosis and mortality were evaluated in patients with COVID-19. Results: The study was completed with 468 patients. The COVID-19 positivity ratio is 43.4%. The solid and hematologic malignancy ratios are 24.1% and 75.9%, respectively, in the positive group. Age, gender, comorbidities, cancer type, and stage, metastasis, and anticancer treatments are similar between the groups (p>0.05). Contact history (p<0.001), musculoskeletal pain (p = 0.015) are more frequent, and CRP (p<0.01), and lactate level (p<0.01) are significantly higher in the COVID-19 group. The mortality rate is 38.4% in the COVID-19-positive group. Most of the non-survivors are male patients with advanced age, solid organ malignancy with lung metastases, with poorer performance status, low blood pressure and oxygen saturation, tachycardia, and tachypnea (p<0.001). WBC, neutrophil, NLR, BUN, phosphorus, AST, GGT, LDH, troponin, fibrinogen, D-Dimer, INR, Ferritin, CRP, PRC, and lactate levels are significantly higher, while lymphocyte, calcium, total protein, and albumin levels are lower (p<0.05) in the non-survivor group. These parameters were identified as risk factors associated with a poor prognosis. Conclusion: The availability of biomarkers that predict adverse clinical outcomes of COVID-19 disease in cancer patients may enable accurate and timely risk assessment, facilitating the early initiation of appropriate treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.